DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT06236672

Completed

Impact of GLP-1 RAs Compared to Basal Insulin Start in Patients Living With Type 2 Diabetes and Chronic Kidney Disease

Impact of Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Compared to Basal Insulin Start on Metabolic Targets in Patients Living With Type 2 Diabetes and Chronic Kidney Disease (Impact GLP-1 CKD)

Asset

GLP-1 / incretin class catch-all

Listed sites

1

Recruiting sites

—

Enrollment

348

actual

Study population

Chronic kidney disease, Type 2 diabetes

Key I/E criteria

•HbA1c ≥7.5%•eGFR 15-59•UACR ≥2

Primary endpoint

•HbA1c, change

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT06236672
Org study IDImpact GLP-1 CKD

Timeline

Milestones

Study start2023-02-15actual
Primary completion2023-11-29actual
Study completion2023-11-29actual
Study first posted2024-02-01actual
Last update posted2024-02-01actual

Assets

Investigational agents

GLP-1 / incretin class catch-all

Study populations

Who this study enrolls

Chronic kidney diseaseType 2 diabetes

Eligibility

Who can enroll

Minimum age18 Years
SexAll
Healthy volunteersNot accepted
Sampling methodProbability sample

Study population text

Adult patients with T2D and CKD with a background antihyperglycemic treatment of an SGLT2i

Inclusion criteria

•18 years or older as of the index date
•Clinical diagnosis of T2D ≥ one year
•Diagnosis of CKD (defined by Diabetes Canada guideline) with eGFR 15-59 ml/min/1.73m2, or eGFR ≥ 60 ml/min/1.73m2 with the uACR ≥ 2mmol/L
•Use of any SGLT2i for more than 6 months
•Baseline HbA1c ≥7.5%

Exclusion criteria

•Clinical diagnosis of type 1 diabetes (T1D)
•Most recent eGFR ≤ 15 ml/min/1.73 m2
•Documented history or family history of Medullary Thyroid Carcinoma or Multiple Endocrine Neoplasia type 2
•Hypersensitivity to GLP-1 RA or any product component
•Initiation of a second AHA therapy on the index date together with GLP-1RA
•Previous use of any GLP-1 RA therapy
•Previous use of basal and bolus insulin therapy
•Participation in a research study with an Investigational Product

Endpoints (1)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Glycemic / diabetes

1 endpoint
Primary/protocol endpoint

change in HbA1c (%)

Time frame:baseline to 26-to-52 weeks follow-up

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.